Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Receptor-positive Metastatic Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT04762979
What this trial is testing

Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer

Who this might be right for
Hormone Receptor Positive Breast CarcinomaHER2-negative Breast CancerPIK3CA Mutant Metastatic Breast Cancer
Marina N Sharifi 44
Testing effectiveness (Phase 2)UnknownNCT04946227
What this trial is testing

Pembrolizumab and Paclitaxel in Hormone Receptor-positive, hyperMUTATted Metastatic Breast Cancer Identified by Whole exOme sequeNcing ('MUTATION2')

Who this might be right for
Breast Cancer
Yonsei University 52
Testing effectiveness (Phase 2)Active Not RecruitingNCT03439735
What this trial is testing

Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC

Who this might be right for
Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 45
Testing effectiveness (Phase 2)Ended earlyNCT05966584
What this trial is testing

Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer

Who this might be right for
Breast Cancer
Memorial Sloan Kettering Cancer Center 1
Testing effectiveness (Phase 2)Looking for participantsNCT05115474
What this trial is testing

Study of Screening Brain MRIs in Stage IV Breast Cancer

Who this might be right for
Triple Negative Breast CancerHER2-positive Breast CancerHormone Receptor-positive Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute 170
Testing effectiveness (Phase 2)Ended earlyNCT01151215
What this trial is testing

Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer

Who this might be right for
NeoplasmsBreast NeoplasmsBreast Cancer
AstraZeneca 482
Testing effectiveness (Phase 2)Study completedNCT04505826
What this trial is testing

A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer

Who this might be right for
Hormone Receptor Positive Breast CarcinomaHER2-negative Breast Cancer
Olema Pharmaceuticals, Inc. 153
Early research (Phase 1)Study completedNCT01808040
What this trial is testing

A Phase 1b Study of TAK-700 in Postmenopausal Women With Hormone-receptor Positive Metastatic Breast Cancer

Who this might be right for
Post Menopausal, Hormone Receptor Positive Breast Cancer
University of Wisconsin, Madison 8
Testing effectiveness (Phase 2)Looking for participantsNCT06224673
What this trial is testing

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

Who this might be right for
HER2 Low Breast CarcinomaTriple Negative Breast CancerHormone-receptor-positive Breast Cancer+1 more
Laura Huppert, MD, BA 36
Testing effectiveness (Phase 2)UnknownNCT02983071
What this trial is testing

G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Carcinoma, Ductal, BreastBreast CancerBreast Neoplasm
G1 Therapeutics, Inc. 102
Early research (Phase 1)Looking for participantsNCT07137871
What this trial is testing

Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy

Who this might be right for
Breast Cancer Metastatic
The University of Texas Health Science Center at San Antonio 35
Testing effectiveness (Phase 2)Study completedNCT02387099
What this trial is testing

Dose EScalation Induction of EvERolimus

Who this might be right for
Breast CancerHormone Receptor Positive Tumor
GBG Forschungs GmbH 156
Testing effectiveness (Phase 2)Active Not RecruitingNCT00585507
What this trial is testing

Efficacy and Safety of 500mg of Fulvestrant

Who this might be right for
Breast Cancer
Beth Israel Deaconess Medical Center 40
Not applicableLooking for participantsNCT04968964
What this trial is testing

Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing

Who this might be right for
Breast CancerCancer of the Breast
Washington University School of Medicine 55
Testing effectiveness (Phase 2)Study completedNCT00534417
What this trial is testing

Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Accelerated Community Oncology Research Network 41
Early research (Phase 1)Ended earlyNCT04726332
What this trial is testing

Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)

Who this might be right for
Neoplasm MalignantEpithelial Ovarian CancerTriple Negative Breast Cancer+2 more
Exelixis 52
Testing effectiveness (Phase 2)Study completedNCT01560416
What this trial is testing

Fulvestrant With or Without Ganetespib in HR+ Breast Cancer

Who this might be right for
Breast Cancer
Dana-Farber Cancer Institute 50
Not applicableEnded earlyNCT03786107
What this trial is testing

HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib

Who this might be right for
Hormone Receptor-Positive, HER2-Negative Metastatic Breast CancerMetastatic Cervical Cancer
Puma Biotechnology, Inc. 1,583
Post-approval studies (Phase 4)Study completedNCT03355157
What this trial is testing

A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).

Who this might be right for
Metastatic Breast Cancer
GBG Forschungs GmbH 130
Early research (Phase 1)Study completedNCT03854903
What this trial is testing

WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor

Who this might be right for
Metastatic Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of BreastHormone Receptor Positive Breast Cancer
Georgetown University 19
Next Page